Zeposia®
Quick Facts
Zeposia® prevents lymphocytes from escaping lymph nodes and attacking nerves in the central nervous system.
Capsule taken orally
Once per day; dosage increased gradually to reduce risk of short-term bradycardia (slow heart rate)
Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS
Potential Benefit:
Zeposia® tested against active comparator (interferon beta-1a injectable):
- 48% fewer relapses
- 48% fewer T2 lesions
- 63% fewer T1 Gd-enhancing lesions
- 9 out of 10 people experienced no disability progression
- These results were equivalent to other leading injectables
Common Potential Side Effects
Upper respiratory infection, elevated liver enzymes, orthostatic hypotension (sudden drop in blood pressure when shifting position), urinary tract infection, back pain, and high blood pressure.
Prescription Assistance:
For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.
DRUGMAKER
Bristol Myers Squibb
HOW Zeposia® WORKS
Zeposia® (ozanimod) is a S1P receptor modulator, which works by blocking the S1P receptor on activated lymphocytes.This keeps these immune cells from moving out of the lymph nodes and into the central nervous system. By trapping the activated cells, it helps prevent damage to the brain and spinal cord.
FDA-Approved
FDA approved in 2020 to treat relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease, in adults.
Potential Side Effects
Upper respiratory infection, elevated liver enzymes, orthostatic hypotension (sudden drop in blood pressure when shifting position), urinary tract infection (UTI), back pain, and high blood pressure. Less common adverse events include an increased risk of infections, heart rhythm issues, liver injury, decline in pulmonary (respiratory) function, and macular edema (swelling behind the eye), and potentially increased risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection that usually leads to death or severe disability over a period of weeks or months.
OTHER KEY INFORMATION
Testing completed prior to starting Zeposia® includes:
- Your healthcare provider may order a blood test of your white blood cells and liver function before you start taking Zeposia
- Your healthcare provider may also order a blood test for the chickenpox virus before starting Zeposia
- An EKG will be performed to make sure you do not have a slow, abnormal or irregular heartbeat
- In some cases, an eye exam may be required
Regular testing completed after starting Zeposia® includes:
- Your doctor may order lab tests of your white blood cells and liver function during your treatment to check your body’s response to Zeposia
When starting Zeposia, please note there is a titration period (starting at a smaller dose and increasing over successive weeks).